Sigma Planning Corp Has $519,000 Stock Position in Humana Inc. (NYSE:HUM)

Sigma Planning Corp trimmed its position in Humana Inc. (NYSE:HUM) by 36.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,134 shares of the insurance provider’s stock after selling 657 shares during the quarter. Sigma Planning Corp’s holdings in Humana were worth $519,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. CWM LLC lifted its stake in shares of Humana by 14.0% in the fourth quarter. CWM LLC now owns 2,330 shares of the insurance provider’s stock worth $1,067,000 after buying an additional 287 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in Humana by 6.3% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 12,584 shares of the insurance provider’s stock valued at $5,761,000 after purchasing an additional 749 shares during the last quarter. Signaturefd LLC raised its stake in Humana by 1.2% during the 4th quarter. Signaturefd LLC now owns 2,634 shares of the insurance provider’s stock valued at $1,206,000 after purchasing an additional 30 shares during the last quarter. Lindbrook Capital LLC raised its stake in Humana by 12.6% during the 4th quarter. Lindbrook Capital LLC now owns 874 shares of the insurance provider’s stock valued at $400,000 after purchasing an additional 98 shares during the last quarter. Finally, abrdn plc raised its stake in Humana by 123.9% during the 4th quarter. abrdn plc now owns 192,600 shares of the insurance provider’s stock valued at $88,174,000 after purchasing an additional 106,586 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Jorge S. Mesquita acquired 545 shares of the firm’s stock in a transaction on Tuesday, February 20th. The shares were purchased at an average price of $367.09 per share, with a total value of $200,064.05. Following the acquisition, the director now directly owns 2,578 shares in the company, valued at $946,358.02. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.32% of the company’s stock.

Humana Stock Down 1.4 %

HUM opened at $311.41 on Friday. The firm’s 50-day simple moving average is $328.56 and its 200-day simple moving average is $395.71. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.59 and a current ratio of 1.67. Humana Inc. has a twelve month low of $299.23 and a twelve month high of $541.21. The firm has a market cap of $37.57 billion, a price-to-earnings ratio of 19.39, a PEG ratio of 1.85 and a beta of 0.45.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, topping the consensus estimate of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The business had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same quarter in the prior year, the firm earned $9.38 EPS. The firm’s quarterly revenue was up 10.7% compared to the same quarter last year. Equities research analysts anticipate that Humana Inc. will post 16.06 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.14%. The ex-dividend date is Friday, June 28th. Humana’s dividend payout ratio is currently 22.04%.

Analyst Ratings Changes

Several research firms recently commented on HUM. Raymond James began coverage on shares of Humana in a research note on Friday, March 22nd. They set a “market perform” rating for the company. Jefferies Financial Group lowered their price target on shares of Humana from $411.00 to $381.00 and set a “buy” rating on the stock in a report on Monday. Oppenheimer lowered their price target on shares of Humana from $415.00 to $370.00 and set an “outperform” rating on the stock in a report on Thursday. Argus lowered shares of Humana from a “buy” rating to a “hold” rating in a report on Wednesday, March 13th. Finally, Royal Bank of Canada lowered their price target on shares of Humana from $415.00 to $353.00 and set an “outperform” rating on the stock in a report on Thursday. Eleven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $433.74.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.